Cabozantinib (XL-184) Monotherapy for Advanced Cholangiocarcinoma
Status:
Completed
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
This research study is evaluating a drug called cabozantinib as a possible treatment cancer
of the bile duct. Cabozantinib is a drug that targets specific pathways inside the cells of
the body. By blocking the c-MET and VEGFR2 pathways from sending signals, cabozantinib may
prevent cells from multiplying. This drug has been used in other research studies and
information from those other research studies suggests that this drug may help to stop the
growth of bile duct cancer.
In this research study, the investigators are looking to see how well cabozantinib works in
slowing the growth of bile duct cancer. The investigators are also assessing the safety and
tolerability of cabozantinib in participants with this type of cancer.